Zai Lab Ltd business relationships
Companies named in Zai Lab Ltd’s 10-K filed 2026-02-26, and public companies whose annual reports name Zai Lab Ltd. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 70 / 100 Top 2% in its category
- Agent readiness
- 20 / 100
- AI adoption
- 0 / 100
Named in Zai Lab Ltd’s annual report 14
“Under this arrangement, Pfizer is the Company's customer and revenue is recognized upon delivery of XACDURO to Pfizer at the contractually agreed prices.” SEC filing
“We will purchase the licensed products exclusively from Pfizer.” SEC filing
“In November 2024, we entered into a strategic collaboration with Pfizer that allows us to leverage the industry-leading commercialization infrastructure of Pfizer's affiliated companies in the anti-infective therapeutic area to support sales of XACDURO in mainland China.” SEC filing
“We will purchase the licensed products exclusively from NovoCure.” SEC filing
“License and Collaboration Agreement with NovoCure (Tumor Treating Fields)” SEC filing
“For example, we rely on argenx for VYVGART and VYVGART Hytrulo, NovoCure for OPTUNE, Deciphera for QINLOCK, Innoviva for XACDURO, and BMS for AUGTYRO.” SEC filing
“We are not otherwise obligated to purchase ZEJULA or other licensed products from GSK.” SEC filing
“License and Collaboration Agreement with GSK (Niraparib)” SEC filing
“We will purchase ZEJULA from GSK for commercial use in Hong Kong.” SEC filing
“License Agreement between Deciphera Pharmaceuticals, LLC and Zai Lab (Shanghai) Co., Ltd. dated June 10, 2019 (incorporated by reference to Exhibit 10.17 to our Annual Report on Form 20-F (File No. 001-38205) filed on April 29, 2020)” SEC filing
“We will purchase the licensed products exclusively from Innoviva.” SEC filing
“License and Collaboration Agreement with Innoviva (SUL-DUR)” SEC filing
“For example, we rely on argenx for VYVGART and VYVGART Hytrulo, NovoCure for OPTUNE, Deciphera for QINLOCK, Innoviva for XACDURO, and BMS for AUGTYRO.” SEC filing
“In January 2025, the Company entered into a license agreement with Zenas BioPharma (HK) Limited ("Zenas"), pursuant to which the Company obtained a license under certain patents and know-how of Zenas to develop and commercialize products containing a differentiated humanized monoclonal antibody targ...” SEC filing
Companies whose annual reports name Zai Lab Ltd 11
“...omotion rights in the U.S. Outside the U.S., Genmab has the sole right to promote Tivdak for second-line plus mCC and has co-promotion rights for other indications in all territories except certain territories where Zai Lab has commercialization rights (mainland China, Hong Kong, Macau, and Taiwan).” SEC filing
“entered into an exclusive out-license agreement with Zai Lab ( Zai Lab Agreement ), a commercial-stage” SEC filing
“regulations may adversely impact our collaboration with Zai Lab in Mainland China, Hong Kong, Taiwan and Macau” SEC filing
“Seagen and Zai Lab announced an exclusive collaboration and license agreement for the development and” SEC filing
“On September 10, 2018, the Company entered into a License and Collaboration Agreement (the "Zai Agreement") with Zai Lab (Shanghai) Co., Ltd. ("Zai") to market the Company's Products in China, Hong Kong, Macau and Taiwan ("Greater China").” SEC filing
“Refer to the out-license agreement with Zai Lab and Everest and the Grant Agreement with Gates Foundation in Note 4, "License, Collaboration and Other Arrangements".” SEC filing
“The increase in XACDURO ® ex-U.S. product sales is attributable mainly to product sales under an interim supply agreement with Zai Lab, which is billed at cost.” SEC filing
“In January 2025, Zenas BioPharma sublicensed their rights under the license agreement to Zai Lab (Hong Kong) Limited ("Zai Lab") and assigned to them the manufacturing development and supply agreement.” SEC filing
“Collaboration revenue - related parties for the years ended December 31, 2025 and 2024 was attributable to our collaboration agreement with Zenas BioPharma and the Side Agreement and MTA with Zai Lab.” SEC filing
“In January 2025, Zenas BioPharma sublicensed their rights under the license agreement to Zai Lab and assigned the Manufacturing Development and Supply Agreement to Zai Lab in connection with the sublicense transaction.” SEC filing
“License Agreement with Zai Lab (Hong Kong) Limited” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.